A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.
A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.
复制标题
DOI：
10.1176/ajp.2007.164.1.160
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
J. Tiihonen;K. Kuoppasalmi;Jaana Föhr;P. Tuomola;Outi Kuikanmäki;H. Vorma;P. Sokero;J. Haukka;E. Meririnne
中科院分区：
文献类型：
--
作者：
J. Tiihonen;K. Kuoppasalmi;Jaana Föhr;P. Tuomola;Outi Kuikanmäki;H. Vorma;P. Sokero;J. Haukka;E. Meririnne
在许多发达国家，与非法使用安非他明有关的问题已成为一个重大的公共卫生问题。迄今为止，关于心理社会治疗有效性的证据仍然有限，而且没有任何药物治疗被证明对安非他明依赖有效。方法符合DSM-IV静脉注射安非他明依赖标准的个体（N=53）被随机分配接受阿立哌唑（15 mg/天）、缓释哌甲酯（54 mg/天）或安慰剂治疗20周。由于中期分析的意外结果，本研究被提前终止。使用意向治疗分析。主要结局指标是安非他明阳性尿液样本的比例。结果阿立哌唑组患者的安非他明阳性尿样明显多于安慰剂组（优势比=3.77,95% CI=1.55-9.18），而哌醋甲酯组患者的安非他明阳性尿样明显少于安慰剂组（优势比=0.46,95% CI=0.26-0.81）。结论哌甲酯是减少严重安非他明依赖患者静脉用药的有效药物。
OBJECTIVE Problems related to illegal amphetamine use have become a major public health issue in many developed countries. To date, evidence on the effectiveness of psychosocial treatments has remained modest, and no pharmacotherapy has proven effective for amphetamine dependence. METHOD Individuals meeting DSM-IV criteria for intravenous amphetamine dependence (N=53) were randomly assigned to receive aripiprazole (15 mg/day), slow-release methylphenidate (54 mg/day), or placebo for 20 weeks. The study was terminated prematurely due to unexpected results of interim analysis. An intention-to-treat analysis was used. The primary outcome measure was the proportion of amphetamine-positive urine samples. RESULTS Patients allocated to aripiprazole had significantly more amphetamine-positive urine samples than patients in the placebo group (odds ratio=3.77, 95% CI=1.55-9.18), whereas patients who received methylphenidate had significantly fewer amphetamine-positive urine samples than patients who had received placebo (odds ratio=0.46, 95% CI=0.26-0.81). CONCLUSIONS Methylphenidate is an effective treatment for reducing intravenous drug use in patients with severe amphetamine dependence.